Search Results - "Efebera, Yvonne Adeduni"

Letermovir prophylaxis and cytomegalovirus reactivation in adult allogeneic hematopoietic cell transplant recipients with graft versus host disease by Wolfe, Delaney, Zhao, Qiuhong, Siegel, Emma G, Puto, Marcin M, Efebera, Yvonne Adeduni, Tossey, Justin C

“…Abstract only 7004 Background: Cytomegalovirus (CMV) is the most common clinically significant infection after allogeneic hematopoietic-cell transplantation…”
Get full text

Race as a predictor of outcome in young patients with myeloma by Cottini, Francesca, Bao, Alicia, Sharma, Nidhi, Khan, Abdullah Mohammad, Bumma, Naresh, Chaudhry, Maria, Devarakonda, Srinivas S., Efebera, Yvonne Adeduni, Rosko, Ashley Elizabeth, Benson, Don M.

“…Abstract only e20019 Background: Multiple myeloma (MM) is a malignancy that affects Black Americans (BA) more often and at earlier age than White Americans…”
Get full text

Daratumumab-induced lymphopenia predicts adverse events and outcomes in patients with myeloma by Cottini, Francesca, Williams, Nita, Bumma, Naresh, Khan, Abdullah Mohammad, Chaudhry, Maria, Devarakonda, Srinivas S., Efebera, Yvonne Adeduni, Benson, Don M., Rosko, Ashley Elizabeth

“…Abstract only e20534 Background: Daratumumab, a monoclonal antibody against CD38, is very effective in patients with Multiple Myeloma (MM). CD38 is expressed…”
Get full text

The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302) by Nishihori, Taiga, Bashir, Qaiser, Pasquini, Marcelo C., Martens, Michael, Wu, Juan, Alsina, Melissa, Efebera, Yvonne Adeduni, Gasparetto, Cristina, Geller, Nancy, Giralt, Sergio, Koreth, John, McCarthy, Philip L., Scott, Emma Catherine, Stadtmauer, Edward Allen, Vesole, David H., Hari, Parameswaran

“…Abstract only 7003 Background: The role of alloHCT and subsequent maintenance for the treatment of high-risk MM has not been fully defined. We evaluated the…”
Get full text

Association of post-transplant outcomes with induction intensity in patients with acute myeloid leukemia by Rebechi, Melanie, Sahasrabudhe, Kieran, Huang, Ying, Elder, Patrick, Blaser, Bradley Wayne, Brammer, Jonathan Edward, Choe, Hannah Kyung, Efebera, Yvonne Adeduni, Eisfeld, Ann-Kathrin, Jaglowski, Samantha, Larkin, Karilyn T.M., Long, Meixiao, Mims, Alice S., Penza, Sam L., Saad, Ayman A., Vasu, Sumithira, Wall, Sarah Allison

“…Abstract only e19026 Background: The USFDA has recently approved several oral targeted therapies for the treatment of acute myeloid leukemia (AML). The…”
Get full text

MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial by Dispenzieri, Angela, Krishnan, Amrita Y., Arendt, Bonnie, Dasari, Surendra, Efebera, Yvonne Adeduni, Geller, Nancy, Giralt, Sergio, Hahn, Theresa, Kohlhagen, Mindy C., Landau, Heather Jolie, Hari, Parameswaran, Pasquini, Marcelo C., Qazilbash, Muzaffar H., McCarthy, Philip L., Shah, Nina, Vesole, David H., Vogl, Dan T., Wallace, Paul K., Stadtmauer, Edward A., Murray, David L.

“…Abstract only 8009 Background: Measuring response among patients with multiple myeloma is essential for the care of patients. Deeper responses have been…”
Get full text

Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM) by Hari, Parameswaran, Pasquini, Marcelo C., Stadtmauer, Edward Allen, Fraser, Raphael, Fei, Mingwei, Devine, Steven Michael, Efebera, Yvonne Adeduni, Geller, Nancy, Horowitz, Mary M., Koreth, John, Landau, Heather Jolie, McCarthy, Philip L., Qazilbash, Muzaffar H., Shah, Nina, Vesole, David H., Vogl, Dan T., Somlo, George, Krishnan, Amrita Y., Giralt, Sergio

“…Abstract only 8506 Background: STaMINA was a phase III trial comparing progression-free survival (PFS) among 758 pts randomized to: 1. second autoHCT then…”
Get full text

Autologous stem cell transplant (ASCT) in myeloma to improve patient reported physical function and fatigue by Bhatt, Geetika, Benson, Don M., Efebera, Yvonne Adeduni, Hofmeister, Craig C., Jaglowski, Samantha Mary, Devine, Steven Michael, Wildes, Tanya Marya, Huang, Ying, Jones, Desiree, Rosko, Ashley Elizabeth

“…Abstract only 10044 Background: Patients with Multiple Myeloma (MM) report some of the poorest Health-related quality of life (HRQoL). Few studies show how…”
Get full text

A feasibility study of electronic geriatric assessment for real-time morbidity evaluation by Bhatt, Geetika, Hofmeister, Craig C., Efebera, Yvonne Adeduni, Benson, Don M., Sborov, Douglas Weston, Jaglowski, Samantha Mary, Devine, Steven Michael, Wildes, Tanya Marya, Jones, Desiree, Huang, Ying, Rosko, Ashley Elizabeth

“…Abstract only…”
Get full text

MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma by Richardson, Paul G., Hofmeister, Craig, Raje, Noopur S., Siegel, David Samuel DiCapua, Lonial, Sagar, Laubach, Jacob, Efebera, Yvonne Adeduni, Vesole, David H., Nooka, Ajay K., Rosenblatt, Jacalyn, Zaki, Mohamed H., Hua, Ye, Li, Yan, Shah, Sheetal, Wang, Jianming, Anderson, Kenneth Carl

“…Abstract only…”
Get full text

MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM) by Richardson, Paul Gerard Guy, Hofmeister, Craig C., Siegel, David Samuel DiCapua, Lonial, Sagar, Laubach, Jacob, Efebera, Yvonne Adeduni, Vesole, David H., Nooka, Ajay K., Rosenblatt, Jacalyn, Raje, Noopur S., Zaki, Mohamed H., Hua, Ye, Shah, Sheetal, Wang, Jianming, Anderson, Kenneth Carl

“…Abstract only 8584 Background: Combinations of lenalidomide (LEN), bortezomib (BORT), and dexamethasone (DEX) have demonstrated preclinical and clinical…”
Get full text